Patent ID: 11946927
Assignee: nan
Field: Pharmaceuticals (Chemistry)
Classification: CPC G  A  Y | IPC A  G

Claim 3:
4. The process of claim 1, wherein if the risk value for the selected individual developing IBD is below the cut-off value for the prediction logistic regression model, the process includes using a second prediction panel of predictive target biomarkers comprising the predictive target biomarkers of sICAM1, GCSF, HP, CRP, RETN and Antibody TT and using a second prediction logistic regression model and the levels of each of the predictive target biomarkers in the second prediction panel of predictive biomarkers and the total level of protein in the blood sample to determine a second risk value, wherein the second prediction logistic regression model is: Log (p/1ip)=1101.571616−0.813305575×deployment−104.1257102×sICAM1−62.63858365×GCSF−5.604142451×sICAM1×GCSF+65.611507602×HP+5.107130532×sICAM1×HP−+1.770741857×RETN and wherein the cut-off value is 0.56; and
wherein if the determined second risk value for the selected individual developing IBD is greater than the cut-off value for the second prediction logistic regression model, the process includes administering a therapy to the selected individual to reduce the risk of the selected individual developing IBD, wherein said therapy includes administering a medication for treating IBD, repeating the process of determining the second risk value for the selected individual developing IBD, wherein if the second risk value increases or remains the same, making modifications to the therapy being administered to the selected individual and repeating the process until the second risk value is below the cut-off value for the second prediction logistic regression model; and
wherein if the second risk value for the selected individual developing IBD is below the cut-off value for the second prediction logistic regression model used for determining the risk value of an individual developing IBD, the process includes using Disease Factors of the selected individual to determine if the process is to be performed again at a future date or administer a therapy to the selected individual when the selected individual is diagnosed with IBD, Crohn's disease or UC for treating IBD, Crohn's disease or UC.